Advertisement
Screener

Grace Therapeutics, Inc. (GRCE) Foreign Currency Transaction Gain (Loss), Unrealized

2.2 / 5 stars · 24/54 Roast Me

Grace Therapeutics, Inc. Foreign Currency Transaction Gain (Loss), Unrealized

Grace Therapeutics, Inc. (GRCE) reported Foreign Currency Transaction Gain (Loss), Unrealized of $0 for the 12-month period ending 2024-03-31, per its 10-K filed 2024-06-21.

Discontinued › Cash Flow › Operating Activities

us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2024-06-21

  • Grace Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2024-03-31 was $0.00.
  • Grace Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2023-12-31 was $0.00.
  • Grace Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
  • Grace Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
  • Grace Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2024 was $0.00.
  • Grace Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2023 was -$5.00K, a 101.35% decline from fiscal 2022.
  • Grace Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2022 was $370.00K.
  • Grace Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2021 was -$814.00K.
Period endForeign Currency Transaction Gain (Loss), Unrealized 3 monthForeign Currency Transaction Gain (Loss), Unrealized 6 monthForeign Currency Transaction Gain (Loss), Unrealized 6 month as first filedForeign Currency Transaction Gain (Loss), Unrealized 9 monthForeign Currency Transaction Gain (Loss), Unrealized 12 month
2024-03-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-21
$0.00
derived: sum of 2 quarters · filed 2024-06-21
$0.00
derived: sum of 3 quarters · filed 2024-06-21
$0.00
10-K · filed 2024-06-21
2023-12-31$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-12
$0.00
derived: sum of 2 quarters · filed 2024-02-12
$0.00
10-Q · filed 2024-02-12
-$33.00K
derived: sum of 4 quarters · filed 2024-06-21
2023-09-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13
$0.00
10-Q · filed 2023-11-13
-$33.00K
derived: sum of 3 quarters · filed 2024-06-21
-$56.00K
derived: sum of 4 quarters · filed 2024-06-21
2023-06-30$0.00
10-Q · filed 2023-08-11
-$33.00K
derived: sum of 2 quarters · filed 2024-06-21
-$56.00K
derived: sum of 3 quarters · filed 2024-06-21
-$15.00K
derived: sum of 4 quarters · filed 2024-06-21
2023-03-31-$33.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-21
-$56.00K
derived: sum of 2 quarters · filed 2024-06-21
-$15.00K
derived: sum of 3 quarters · filed 2024-06-21
-$5.00K
10-K · filed 2024-06-21
2022-12-31-$23.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-12
$18.00K
derived: sum of 2 quarters · filed 2024-02-12
$28.00K
10-Q · filed 2024-02-12
-$20.00K
derived: sum of 4 quarters · filed 2024-02-12
2022-09-30$41.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13
$51.00K
10-Q · filed 2023-11-13
$3.00K
derived: sum of 3 quarters · filed 2023-11-13
$1.00K
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30$10.00K
10-Q · filed 2023-08-11
-$38.00K
derived: sum of 2 quarters · filed 2023-08-11
-$40.00K
derived: sum of 3 quarters · filed 2023-08-11
$1.12M
derived: sum of 4 quarters · filed 2023-08-11
2022-03-31-$48.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-23
-$50.00K
derived: sum of 2 quarters · filed 2023-06-23
$1.11M
derived: sum of 3 quarters · filed 2023-06-23
$370.00K
10-K · filed 2023-06-23
2021-12-31-$2.00K
10-Q · filed 2022-02-14
$1.16M
derived: sum of 2 quarters · filed 2022-02-14
$418.00K
10-Q · filed 2023-02-14
-$602.00K
derived: sum of 4 quarters · filed 2022-08-11
2021-09-30$1.16M
10-Q · filed 2021-11-10
-$420.00K
10-Q · filed 2022-11-14
$420.00K
10-Q · filed 2021-11-10
-$600.00K
derived: sum of 3 quarters · filed 2022-08-11
-$546.00K
derived: sum of 4 quarters · filed 2022-08-11
2021-06-30-$740.00K
10-Q · filed 2022-08-11
-$1.76M
derived: sum of 2 quarters · filed 2022-08-11
-$1.71M
derived: sum of 3 quarters · filed 2022-08-11
-$1.69M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31-$1.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-21
-$968.00K
derived: sum of 2 quarters · filed 2022-06-21
-$948.00K
derived: sum of 3 quarters · filed 2022-06-21
-$814.00K
10-K · filed 2022-06-21
2020-12-31$54.00K
10-Q · filed 2022-02-14
$74.00K
derived: sum of 2 quarters · filed 2022-02-14
$208.00K
10-Q · filed 2022-02-14
-$38.00K
derived: sum of 4 quarters · filed 2022-02-14
2020-09-30$20.00K
10-Q · filed 2021-11-10
$154.00K
10-Q · filed 2021-11-10
-$92.00K
derived: sum of 3 quarters · filed 2021-11-10
$10.00K
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30$134.00K
10-Q · filed 2021-08-12
-$112.00K
derived: sum of 2 quarters · filed 2021-08-12
-$10.00K
derived: sum of 3 quarters · filed 2021-08-12
-$74.00K
derived: sum of 4 quarters · filed 2021-08-12
2020-03-31-$246.00K
10-K · filed 2020-06-29
-$144.00K
derived: sum of 2 quarters · filed 2021-02-09
-$208.00K
derived: sum of 3 quarters · filed 2021-02-09
-$246.00K
10-K · filed 2021-06-22
2019-12-31$102.00K
10-Q · filed 2021-02-09
$38.00K
derived: sum of 2 quarters · filed 2021-02-09
$151.00K
10-Q · filed 2021-02-09
-$282.00K
derived: sum of 4 quarters · filed 2021-02-09
2019-09-30-$64.00K
10-Q · filed 2020-11-16
$45.00K
10-Q · filed 2020-11-16
-$384.00K
derived: sum of 3 quarters · filed 2020-11-16
2019-06-30$60.00K
10-Q · filed 2020-08-13
-$320.00K
derived: sum of 2 quarters · filed 2020-08-13
2019-03-31-$380.00K
10-K · filed 2020-06-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
PDS Biotechnology Corp (PDSB)United States$0.045B
SCYNEXIS INC (SCYX)United States$0.045B
Werewolf Therapeutics, Inc. (HOWL)United States$0.047B
VERU INC. (VERU)United States$0.043B-3.93
Dogwood Therapeutics, Inc. (DWTX)United States$0.049B
Lite Strategy, Inc. (LITS)United States$0.049B
Elicio Therapeutics, Inc. (ELTX)United States$0.049B
Kairos Pharma, LTD. (KAPA)United States$0.041B
Incannex Healthcare Inc. (IXHL)$0.040B-22.32
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98